Indiana is currently home to 1224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Urothelial Carcinoma, Bladder Cancer
Register for Updates
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institution - 0058, Anderson, Indiana
Conditions: Multiple Myeloma
Register for Updates
Safety and Efficacy of VDPHL01 in Males and Females with AGA
NCT06527365
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness. This multiple center, open-label, study will last about 13 months and inc... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/27/2025
Locations: 04, New Albany, Indiana
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Community Health Network, Indianapolis, Indiana
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
NCT04555161
Recruiting
This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: St. Vincent Health, Indianapolis, Indiana
Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
Register for Updates
Fecal Microbiota Transplant National Registry
NCT03325855
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Register for Updates
Post-Operative Thoracolumosacral Orthosis for PJK
NCT06491030
Recruiting
Proximal junctional kyphosis (PJK) is a common post-operative radiographic finding after surgery for adult spinal deformity (ASD) patients. Although the clinical relevance of isolated PJK is unclear, PJK can progress to symptomatic proximal junctional failures which requires a large revision surgery. Currently, post-operative bracing with a thoracolumbosacral orthosis (TLSO) is common practice after spinal deformity surgery, however the efficacy of this in preventing PJK is unknown. This multi-c... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
01/24/2025
Locations: Indiana Spine Group, Carmel, Indiana
Conditions: Proximal Junctional Kyphosis, Adult Spinal Deformity Surgery, Thoracolumbosacral Orthosis
Register for Updates
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT05557877
Recruiting
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
01/24/2025
Locations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Breast Carcinoma
Register for Updates
Interaction of CYP2B6 Genotype and Efavirenz with Methadone and Tizanidine PK
NCT05789173
Recruiting
The main goal of this clinical study is to test how CYP2B6 genetic variations and efavirenz (cornerstone in HIV-1 therapy) dictate the disposition (PK) of CYP2B6 substrate (methadone) and PK and effect (PD) of CYP1A2 substrate (tizanidine). Specifically, the investigators will test whether efavirenz produces CYP2B6 genotype dependent unanticipated DDIs with CYP2B6 (methadone) and CYP1A2 (tizanidine), leading to lack of efficacy or increased toxicity. Healthy volunteers genotyped for CYP2B6\*6 an... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/23/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Drug-Drug Interaction
Register for Updates
Plasma Rich in Growth Factors in Corneal Endothelial Transplantation
NCT06261346
Recruiting
The purpose of the study is to determine the safety and efficacy of brief intraoperative corneal endothelial graft incubation in plasma rich in growth factors (PRGF) for reducing postoperative endothelial cell loss.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: Price Vision Group, Indianapolis, Indiana
Conditions: Fuchs' Endothelial Dystrophy, Corneal Edema
Register for Updates
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
NCT02493478
Recruiting
Advanced airway interventions are common high risk, high stakes events for children in intensive care units (ICU) and emergency departments (ED), with risk for life and health threatening consequences.
Gender:
ALL
Ages:
All
Trial Updated:
01/21/2025
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Register for Updates
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
Recruiting
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Northwest Cancer Center, Dyer, Indiana
Conditions: Endometrial Cancer
Register for Updates